Cyclosporin, also referred to as cyclosporin A or cyclosporine, is a cyclic polypeptide of fungal origin, composed of 11 amino-acid residues, with a potent suppressive activity on both cell-mediated and humoral immunity. Although the mechanism of action has not yet been completely clarified, it is generally agreed that the drug acts at an early stage of T cell activation [1, 2] .
Since the first studies in clinical organ transplantation [3, 4] , much interest has been shown in this drug. Recently some multicentre studies have reported encouraging results obtained on large-scale trials with cyclosporin in cadaveric renal transplantation, in comparison with those obtained with conventional therapies including azathioprine [5, 6] .
No data, except for some preliminary reports from our group [7] and from the University of Minnesota [8] , have appeared on the effects of cyclosporin in human pancreatic transplantation. It seems rational to employ cyclosporin as the immunosuppressant in pancreaticorenal transplantation in order to confirm the results obtained with other organ transplantations, and with the aim of reducing or eliminating steroids from the treatment, thus achieving a better control of carbohydrate metabolism.
At the Herriot Hospital, Lyon, the therapy of choice for Type 1 diabetic patients with end-stage renal failure consists, in the absence of related kidney donors, of double simultaneous kidney plus pancreatic transplantation from cadaveric donors. In these patients the use of cyclosporin was commenced in June 1981.
We report the results of our continuing experience (30 months) of the use of cyclosporin in clinical pancreatic transplantation, either as an initial immunosuppressant or as a replacement agent after a conventional course of immunosuppression with azathioprine, in comparison with historical control subjects of the precyclosporin era (1978) (1979) (1980) (1981) .
Subjects and methods

Subjects
Between September 1978 and December 1983, 33 patients received primary double simultaneous pancreatic plus kidney transplantations from cadaveric donors. They all had Type I diabetes complicated by end-stage renal failure due to nephropathy. Their mean +_ SEM age was 35.8 + 1.5 years, and their mean duration of diabetes 20_+ 1 years. Twenty-eight patients (85%) were on maintenance dialysis at the time of transplantation, with a duration of dialysis of 17.0_+ 2.3 months. All patients were affected by severe macro-and microangiopathy, five (15%) having undergone at least one amputation and seven (21%) being completely blind at the time of transplantation.
Donors were heart-beating cadavers, matched with the recipients on the basis of ABO-compatibility and negative cross-match. The .* The mortality distribution in protocol C was four before and two after the switching to cyclosporin number of HLA-A and -B antigens shared between donors and recipients was none in 13 cases, one in 15 cases, two in four cases and three in one case. All patients had received deliberate blood transfusions before transplantation as immunological conditioning. The pancreatic transplantation technique has been described in detail elsewhere [91.
Analysis
The rates of survival for patients and grafts were calculated according to the actuarial method [10] .
Results
The status of patients, renal and pancreatic grafts on 31 December 1983 is summarized in Table 1 . Seventeen patients (51%) were alive, 11 (33%) with both renal and pancreatic grafts functioning, four (12%) with only the renal graft functioning, and one with only the pancreatic graft functioning. The overall patient survival was 75% at 3 months, 67% at 6 months, 63% at 1 year, 51% at 2 years and 32% at 3 years. The overall renal graft survival was 75% at 3months, 63% at 6months, 51% at 1 year, 31% at 2years and 22% at 3 years. The overall pancreatic graft survival was 62% at 3 months, 51% at 6months, 36% at lyear, 24% at 2years and 12% at 3 years. Different results were obtained with the three protocols. With protocol A the patient survival rate was 75% at 3 and 6 months and 1 year, 50% at 2 years and 25% at 3 years. With protocol B, patient survival was 86% at 3 months, 72% at 6 months, 67% at 1 and 2 years. With protocol C the patient survival was 65% at 3 and 6 months, 1, 2 and 3 years (Fig. 1) .
With protocol A the pancreatic graft survival rate was 63% at 3 months, 38% at 6 months and 1 year, and 13% at 2 years. With protocol B the pancreatic graft survival was 72% at 3 months, 57% at 6 months, 29% at 1 and 2 years. With protocol C, the pancreatic graft survival was 69% at 3 and 6 months, 39% at 1, 2 and 3 years (Fig. 1) .
Altogether 21 pancreatic graft failures occurred. Eleven were due to the death of the patient (three in protocol A, three in protocol B and five in protocol C; in the latter group, three occurred before the switch to cyclosporin), five were due to vascular thrombosis (two in protocol A, three in protocol C), and four were due to rejection (three in protocol A and one in protocol B).
Discussion
Although recent technical improvements have generated new interest in pancreatic transplantation, the success rate of this procedure still remains relatively low [11] . The main causes of failure are technical complications, rejection and death. Our results, although based on a relatively small number of patients, seem to indicate that the use of cyclosporin has not improved the short-term rate of success of simultaneous kidney plus pancreatic transplantation. In fact the patient and the pancreatic graft survivals at 3 and 6months and at 1 year were similar under the three treatment protocols. In contrast, the patient and pancreatic graft survivals were improved in the cyclosporin-treated groups at 2 and, at least for protocol C, 3 years. However, this improvement cannot be attributed with certainty to cyclosporin. Indeed, the allocation of patients to different groups of therapy was not randomized and the patients treated with conventional therapy were an historical group of the pre-cyclosporin period. Therefore, additional factors other than immunosuppressive treatment, such as accumulation of experience and continuing improvements in technique, could have partially contributed to the improvement of the results. It is, nevertheless, interesting to note that among a total of 13 failures only one pancreatic graft was lost because of rejection in protocols B and C, while among the eight failures with conventional therapy, three were due to rejection. Although still anecdotal, this observation might reflect a real capacity of cyclosporin to control the pancreatic rejection better.
In conclusion, our experience with cyclosporin in clinical pancreatic transplantation does not seem to be as impressive as for other organ transplantations, in agreement with the observations from the University of Minnesota [8] . This could be explained on the basis of the still relatively poor results of pancreatic transplanta-J. Traeger et al.: Cyclosporin in pancreatic transplantation tion, due to the persisting technical problems and to the poor clinical condition of many recipients at the time of transplantation. However a decreased incidence of rejection and improved long-term survival of patients and grafts have been observed in our experience with cyclosporin. This possible positive trend can only be confirmed by further follow-up and experience.
